Eingeschränkte vs Ausgedehnte Lymphadenektomie LEA

Conditions

Bladder Cancer

Keywords

Lymphadenectomy, Extension, Bladder cancer

Brief summary

This trial evaluates the therapeutic benefit of extended versus limited lymphadenectomy at the time of radical cystectomy in patients with bladder cancer.

Detailed description

The extent of pelvic lymphadenectomy in the surgical treatment of muscle-invasive, clinically locally bladder cancer is not yet standardized. There are no data from randomized, prospective studies on the prognostic role of regional lymphadenectomy. Results of retrospective studies suggest, that the prognosis of patients with muscle-invasive bladder cancer can be improved by extending the limits of pelvic lymphadenectomy. Furthermore it could be demonstrated in a prospective study that the pattern of metastasis of bladder cancer has a high variability. About two-thirds of lymph node metastases are found outside the normally cleared areas of lymphadenectomy. In this study patients will be randomized into arms with limited versus extended lymphadenectomy. The limited lymphadenectomy includes the removal of the obturatoric, external and internal iliac lymph nodes, the extended one includes the removal of all lymph nodes between pelvic floor and the inferior mesenteric artery. The primary objective of the study is to detemine the influence of limited versus extended lyphadenectomy at the time of radical cystectomy on recurrence-free survival. Secondary study objectives include the influence on cancer-specific survival, overall survival, complication rates, histopathologic N-stage, the localization of recurrence and influence of adjuvant chemotherapy . Adjuvant chemotherapy is optional and is recommended in patients with locally advanced disease (pT3/4) or regional lymph node metastasis (pN+).

Heck MM, Lehmann J, Amiel T, Rübben H, Albers P, Wolff JM, Frohneberg D, de Geeter P, Heidenreich A, Kälble T, Stöckle M, Schnöller T, Stenzl A, Müller M, Truss M, Roth S, Liehr UB, Leißner J, Bregenzer T, Rexer H, Retz M, Gschwend JE.

2025-09-171 citations

10.1016/j.eururo.2025.09.001

Molecular lymph node staging for bladder cancer patients undergoing radical cystectomy with pelvic lymph node dissection.

Heck MM, Koll FJ, Retz M, Autenrieth M, Magg K, Lunger L, Gschwend JE, Nawroth R.

2020-03-045 citations

10.1016/j.urolonc.2020.01.018

Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial.

Gschwend JE, Heck MM, Lehmann J, Rübben H, Albers P, Wolff JM, Frohneberg D, de Geeter P, Heidenreich A, Kälble T, Stöckle M, Schnöller T, Stenzl A, Müller M, Truss M, Roth S, Liehr UB, Leißner J, Bregenzer T, Retz M.

2018-10-15228 citations

10.1016/j.eururo.2018.09.047

Limited versus extended pelvic lymphadenectomy in patients with bladder cancer undergoing radical cystectomy: Survival results from a prospective, randomized trial (LEA AUO AB 25/02).

Juergen E. Gschwend, Matthias Heck, Jan Lehmann, Herbert Ruebben, Peter Albers et al. (19 authors)

Journal of Clinical Oncology2016-05-2034 citations

10.1200/jco.2016.34.15_suppl.4503

Interventions

PROCEDURElimited lymphadenectomy

Field 5 (Group external iliac rigt) Field 7 (Group external iliac left) Field 9 (obturatorical Group right) Field 11 (obturatorical Group left) Field 13 (Group internal iliac right) Field 14 (Group internal iliac left)

PROCEDUREextended lymphadenectomy

Field 1 (paracaval right) Field 2 (interaortocaval) Field 3 (paraaortal left) Field 4 (Group iliac artery right) Field 5 (Group external iliac rigt) Field 6 (Group iliac artery left) Field 7 (Group external iliac left) Field 8 (presacral) Field 9 (obturatorical Group right) Field 10 (deep obturatorical Group right) Field 11 (obturatorical Group left) Field 12 (deep obturatorical Group left) Field 13 (Group internal iliac right) Field 14 (Group internal iliac left)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* Histologically proven, invasive urothelial bladder cancer, locally completely resectable (T1G3 - T4a, Nx) * Age \>= 18 years * Written consent of the patient * Patient compliance and geographic proximity to allow adequate follow-up

Exclusion criteria

* Histologically or by imaging diagnostics proven organ metastases * Radiographic evidence of enlarged lymph nodes (\> 1 cm) above the aortic bifurcation in conjunction with pelvic lymph node metastases * Radiographic or other evidence of T4b-tumor (infiltration of the pelvic wall or other organ systems) * Prior neoadjuvant chemotherapy of bladder cancer * Prior previous pelvic lymphadenectomy * Prior radiotherapy to the pelvis * internal medical or anesthetic risk factors that require a short operation time * Palliative cystectomy (f.e. bulky-disease, infiltration of adjacent structures) * Evidence of another tumor restricting life expectancy of the patient

Design outcomes

Primary

Measure	Time frame	Description
Recurrence free Survival (RFS)	5 years	Definition Recurrence-free survival: Time from radical cystectomy to tumor reccurence or death from any cause up to 5 years

Secondary

Measure	Time frame	Description
Overall survival (OS)	5 years	Definition Overall survival: Time from radical cystectomy to death from any cause up to 5 years
Determination of type and location of tumour progression(local recurrences and distant metastases)	5 years	—
Cancer specific survival (CSS)	5 years	Definition Cancer-specific suvival: Time from radical cystectomy to death from bladder cancer up to 5 years
Influence of adjuvant chemotherapy (by subgroup analysis)	5 years	—
Documentation of complications	5 years	—
Effect on histopathological stage (Will Rogers phenomenon)	5 years	Definition Effect on histopathologic stage: Influence of extended lymphadenectomy on detection of lymph node metastasis

Countries

Germany

Outcome results

None listed